Paclitaxel is under clinical development by DAE HWA Pharmaceutical and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase II drugs for Metastatic Breast Cancer have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Paclitaxel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Paclitaxel overview
Paclitaxel (DHP-107, Liporaxel) is a taxane derivative, acts as anti-neoplastic agent. It is formulated as a liposomal solution for oral route of administration. Paclitaxel is indicated for the treatment of metastatic and locally recurrent gastric cancer.
Paclitaxel is under development for the treatment of metastatic HER2 negative and hormone sensitive breast cancer, knee cancer, oesophagal cancer, ovarian cancer angiosarcoma, bladder cancer, cervical cancer, head and neck cancer, Kaposi's sarcoma and lung cancer. The drug candidate is developed based on DaeHwa lipid-based self-emulsification delivery (DH-LASED) technology.
DAE HWA Pharmaceutical overview
DAE HWA Pharmaceutical (DAE HWA) is a biotechnology company that develops, manufactures and markets prescription, over-the-counter and finished pharmaceutical products. The company’s products comprise analgesics, injections, anti-inflammatory enzymes, vitamins and tonics, plaster, antihistamines, skeletal muscle relaxants, expectorants and mucolytics among others. DAE HWA also offers drugs for liver diseases, drugs for hemorrhoid disease, gastrointestinal drugs, anti-inflammatory drugs, topical drugs, cardiovascular drugs and drugs for the central nervous system. The company operates with a manufacturing facility in South Korea. DAE HWA is headquartered in Seoul, South Korea.
For a complete picture of Paclitaxel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
